\
&
Contact us
\
&
Contact us
This was 4 months ago
LocationBrussels, Belgium
This event is jointly organised by the Mission of Switzerland to the EU, the Paul Scherrer Institute (PSI), the European Molecular Biology Laboratory (EMBL) and SwissCore: “In light of the discussions towards the next EU framework programme for research and innovation (FP10) and the second European Research Area (ERA) Policy Agenda 2025-2027, this event explores how Research Infrastructures (RIs) can play a decisive role in advancing Europe’s competitiveness and addressing the acute skills gap in the age of AI. Examples of leading European research and competence centres that are shaping the future of science will be presented: the PSI, part of the ETH domain in Switzerland, offering a unique array of large research infrastructures and highly competitive research activities in basic and applied sciences, and the EMBL, Europe’s only international life sciences research organisation and member of the European Intergovernmental Research Organisation Forum (EIROForum). In the panel the following questions will be addressed:
The programme and registration form are available in the event announcement on the Swisscore website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
